Advertisement
Advertisement
BLTE
Belite Bio, Inc - ADR
173.53
USDSponsored
-7.64
-4.22%
Apr 10, 15:58 UTC -4
Closed
After-Market
174.87
+1.34
+0.77%
BLTE Earnings Reports
Positive Surprise Ratio
BLTE beat 5 of 14 last estimates.
36%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.64
Implied change from Q4 25 (Revenue/ EPS)
--
/-8.57%
Implied change from Q1 25 (Revenue/ EPS)
--
/+42.22%
Belite Bio, Inc - ADR earnings per share and revenue
On Mar 02, 2026, BLTE reported earnings of -0.70 USD per share (EPS) for Q4 25, missing the estimate of -0.55 USD, resulting in a -25.63% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.68% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.64 USD, with revenue projected to reach -- USD, implying an decrease of -8.57% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Belite Bio, Inc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Belite Bio, Inc - ADR reported EPS of -$0.70, missing estimates by -25.63%, and revenue of $0.00, 0% as expectations.
How did the market react to Belite Bio, Inc - ADR's Q4 2025 earnings?
The stock price moved down -6.68%, changed from $190.30 before the earnings release to $177.58 the day after.
When is Belite Bio, Inc - ADR expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Belite Bio, Inc - ADR's next earnings report?
Based on 6
analysts, Belite Bio, Inc - ADR is expected to report EPS of -$0.64 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement